Rafael (RFL) Competitors $2.00 +0.05 (+2.68%) (As of 12:50 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RFL vs. ENTA, ADCT, LXRX, NKTR, DMAC, NBTX, VSTM, GALT, INZY, and NKTXShould you be buying Rafael stock or one of its competitors? The main competitors of Rafael include Enanta Pharmaceuticals (ENTA), ADC Therapeutics (ADCT), Lexicon Pharmaceuticals (LXRX), Nektar Therapeutics (NKTR), DiaMedica Therapeutics (DMAC), Nanobiotix (NBTX), Verastem (VSTM), Galectin Therapeutics (GALT), Inozyme Pharma (INZY), and Nkarta (NKTX). These companies are all part of the "pharmaceutical preparations" industry. Rafael vs. Enanta Pharmaceuticals ADC Therapeutics Lexicon Pharmaceuticals Nektar Therapeutics DiaMedica Therapeutics Nanobiotix Verastem Galectin Therapeutics Inozyme Pharma Nkarta Enanta Pharmaceuticals (NASDAQ:ENTA) and Rafael (NYSE:RFL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Do analysts rate ENTA or RFL? Enanta Pharmaceuticals presently has a consensus price target of $20.00, suggesting a potential upside of 114.59%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Enanta Pharmaceuticals is more favorable than Rafael.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Rafael 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor ENTA or RFL? In the previous week, Rafael had 26 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 26 mentions for Rafael and 0 mentions for Enanta Pharmaceuticals. Rafael's average media sentiment score of 0.32 beat Enanta Pharmaceuticals' score of 0.00 indicating that Rafael is being referred to more favorably in the news media. Company Overall Sentiment Enanta Pharmaceuticals Neutral Rafael Neutral Do institutionals and insiders hold more shares of ENTA or RFL? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, ENTA or RFL? Rafael has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$79.20M2.49-$133.82M-$5.45-1.71Rafael$640K77.18-$34.41M-$1.45-1.38 Which has more volatility & risk, ENTA or RFL? Enanta Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Rafael has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Does the MarketBeat Community believe in ENTA or RFL? Enanta Pharmaceuticals received 315 more outperform votes than Rafael when rated by MarketBeat users. Likewise, 56.76% of users gave Enanta Pharmaceuticals an outperform vote while only 0.00% of users gave Rafael an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes31556.76% Underperform Votes24043.24% RafaelOutperform VotesNo VotesUnderperform Votes2100.00% Is ENTA or RFL more profitable? Enanta Pharmaceuticals has a net margin of -160.27% compared to Rafael's net margin of -5,401.88%. Rafael's return on equity of -43.68% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-160.27% -63.75% -27.09% Rafael -5,401.88%-43.68%-40.78% SummaryEnanta Pharmaceuticals beats Rafael on 11 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Rafael News Delivered to You Automatically Sign up to receive the latest news and ratings for RFL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RFL vs. The Competition Export to ExcelMetricRafaelPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$47.13M$6.49B$5.07B$19.96BDividend YieldN/A8.11%4.99%3.49%P/E Ratio-1.344.8587.8636.42Price / Sales75.17374.821,228.8217.94Price / CashN/A52.5939.5121.28Price / Book0.5610.216.944.59Net Income-$34.41M$153.61M$119.12M$985.93M7 Day Performance5.98%-2.00%-1.84%0.45%1 Month Performance5.98%-7.47%-3.65%1.05%1 Year Performance8.33%31.80%31.64%24.67% Rafael Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RFLRafael0.596 of 5 stars$2.00+2.7%N/A+8.3%$49.40M$640,000.00-1.3813ENTAEnanta Pharmaceuticals2.9602 of 5 stars$9.32+2.6%$20.00+114.6%+1.6%$197.49M$79.20M-1.67145ADCTADC Therapeutics2.8921 of 5 stars$2.02+2.0%$8.25+308.4%+177.9%$195.31M$69.56M0.00310Positive NewsLXRXLexicon Pharmaceuticals1.9831 of 5 stars$0.79-2.2%$6.00+659.5%-31.6%$194.53M$1.20M0.00285Analyst RevisionNKTRNektar Therapeutics4.1024 of 5 stars$1.00flat$3.50+250.0%+92.3%$184.46M$90.12M0.00220DMACDiaMedica Therapeutics1.9115 of 5 stars$4.25+5.7%$7.00+64.7%+62.8%$181.73MN/A0.0020High Trading VolumeNBTXNanobiotix2.3432 of 5 stars$3.80-6.6%$11.50+202.6%-33.5%$179.09M$39.18M0.00100Positive NewsVSTMVerastem2.8014 of 5 stars$4.01+5.8%$12.50+211.7%-41.2%$178.49M$2.60M-1.1950Analyst DowngradeAnalyst RevisionNews CoverageGALTGalectin Therapeutics1.7149 of 5 stars$2.84+0.7%$11.00+287.3%+50.8%$178.24MN/A0.009Analyst UpgradeAnalyst RevisionNews CoverageINZYInozyme Pharma1.2361 of 5 stars$2.73-2.2%$15.71+475.6%-28.5%$175.38MN/A-1.7050NKTXNkarta3.1214 of 5 stars$2.48-0.8%$15.00+504.8%-4.4%$175.01MN/A-1.33140Analyst Forecast Related Companies and Tools Related Companies ENTA Alternatives ADCT Alternatives LXRX Alternatives NKTR Alternatives DMAC Alternatives NBTX Alternatives VSTM Alternatives GALT Alternatives INZY Alternatives NKTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RFL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rafael Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rafael With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RFL Stock Alerts